The Efficacy of Tumor-dormancy Therapy Using an Angiogenesis Inhibitor and Differentiation Agents for Dogs with Skeletal or Extraskeletal Osteosarcoma

Abstract

Tumor-dormancy therapy using an angiogenesis inhibitor and two differentiation agents as clinical trials was employed to treat two dogs with skeletal or extraskeletal osteosarcoma, respectively. Because, in both cases, QOL was well maintained and tumor progression was slow, the tumor-dormancy therapy seems effective as a treatment for dogs with osteosarcoma.